Immunotherapyresponsive dementias and encephalopathies

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The diagnosis of an autoimmune dementia requires the detection of objective improvements in cognitive decline (usually subacute in onset with a fluctuating course) after a course of immunotherapy. Serum and CSF antibody markers of autoimmunity (particularly those with neural antigen specificity) as well as other CSF markers of inflammation increase the suspicion for an autoimmune cause. The detection of neural autoantibodies should raise concern for a paraneoplastic etiology and may inform a targeted oncologic evaluation (eg, NMDA receptor antibodies are associated with teratoma). MRI, EEG, functional imaging, and neuropsychological evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured. Most treatment information emanates from retrospective case series and expert opinion. Nonetheless, early intervention allows reversal of deficits in many patients. Chronic treatment is often required to maintain remission.

Original languageEnglish (US)
Pages (from-to)80-101
Number of pages22
JournalCONTINUUM Lifelong Learning in Neurology
Volume16
Issue number2
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Brain Diseases
Immunotherapy
Dementia
Antibodies
Teratoma
Expert Testimony
Neurologic Manifestations
N-Methyl-D-Aspartate Receptors
Autoimmunity
Autoantibodies
Electroencephalography
Magnetic Resonance Imaging
Inflammation
Antigens
Therapeutics
Serum
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Immunotherapyresponsive dementias and encephalopathies. / McKeon, Andrew B; Lennon, Vanda A; Pittock, Sean J.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 16, No. 2, 04.2010, p. 80-101.

Research output: Contribution to journalArticle

@article{8f06eb85fc9e4eaea04b42db65c18629,
title = "Immunotherapyresponsive dementias and encephalopathies",
abstract = "The diagnosis of an autoimmune dementia requires the detection of objective improvements in cognitive decline (usually subacute in onset with a fluctuating course) after a course of immunotherapy. Serum and CSF antibody markers of autoimmunity (particularly those with neural antigen specificity) as well as other CSF markers of inflammation increase the suspicion for an autoimmune cause. The detection of neural autoantibodies should raise concern for a paraneoplastic etiology and may inform a targeted oncologic evaluation (eg, NMDA receptor antibodies are associated with teratoma). MRI, EEG, functional imaging, and neuropsychological evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured. Most treatment information emanates from retrospective case series and expert opinion. Nonetheless, early intervention allows reversal of deficits in many patients. Chronic treatment is often required to maintain remission.",
author = "McKeon, {Andrew B} and Lennon, {Vanda A} and Pittock, {Sean J}",
year = "2010",
month = "4",
doi = "10.1212/01.CON.0000368213.63964.34",
language = "English (US)",
volume = "16",
pages = "80--101",
journal = "Continuum (Minneapolis, Minn.)",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Immunotherapyresponsive dementias and encephalopathies

AU - McKeon, Andrew B

AU - Lennon, Vanda A

AU - Pittock, Sean J

PY - 2010/4

Y1 - 2010/4

N2 - The diagnosis of an autoimmune dementia requires the detection of objective improvements in cognitive decline (usually subacute in onset with a fluctuating course) after a course of immunotherapy. Serum and CSF antibody markers of autoimmunity (particularly those with neural antigen specificity) as well as other CSF markers of inflammation increase the suspicion for an autoimmune cause. The detection of neural autoantibodies should raise concern for a paraneoplastic etiology and may inform a targeted oncologic evaluation (eg, NMDA receptor antibodies are associated with teratoma). MRI, EEG, functional imaging, and neuropsychological evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured. Most treatment information emanates from retrospective case series and expert opinion. Nonetheless, early intervention allows reversal of deficits in many patients. Chronic treatment is often required to maintain remission.

AB - The diagnosis of an autoimmune dementia requires the detection of objective improvements in cognitive decline (usually subacute in onset with a fluctuating course) after a course of immunotherapy. Serum and CSF antibody markers of autoimmunity (particularly those with neural antigen specificity) as well as other CSF markers of inflammation increase the suspicion for an autoimmune cause. The detection of neural autoantibodies should raise concern for a paraneoplastic etiology and may inform a targeted oncologic evaluation (eg, NMDA receptor antibodies are associated with teratoma). MRI, EEG, functional imaging, and neuropsychological evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured. Most treatment information emanates from retrospective case series and expert opinion. Nonetheless, early intervention allows reversal of deficits in many patients. Chronic treatment is often required to maintain remission.

UR - http://www.scopus.com/inward/record.url?scp=77957951073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957951073&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000368213.63964.34

DO - 10.1212/01.CON.0000368213.63964.34

M3 - Article

VL - 16

SP - 80

EP - 101

JO - Continuum (Minneapolis, Minn.)

JF - Continuum (Minneapolis, Minn.)

SN - 1080-2371

IS - 2

ER -